Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Fernando Mendoza prominently mentioned his mother in his Heisman Trophy acceptance speech. Here's what you should know about ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

New Swedish research finds that people with highest microplastics and PFAS levels face double the risk of multiple sclerosis ...

Exposure to common environmental chemicals, especially in combination, is linked to an increased risk of multiple sclerosis.